Skip to main content
Erschienen in: BMC Infectious Diseases 1/2017

Open Access 01.12.2017 | Case report

Streptococcal toxic shock syndrome caused by the dissemination of an invasive emm3/ST15 strain of Streptococcus pyogenes

verfasst von: Tsuyoshi Sekizuka, Emina Nai, Tomohiro Yoshida, Shota Endo, Emi Hamajima, Satoka Akiyama, Yoji Ikuta, Natsuko Obana, Takahiro Kawaguchi, Kenta Hayashi, Masahiro Noda, Tomoko Sumita, Masayuki Kokaji, Tatsuo Katori, Masanori Hashino, Kunihiro Oba, Makoto Kuroda

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2017

Abstract

Background

Streptococcus pyogenes (group A Streptococcus [GAS]) is a major human pathogen that causes a wide spectrum of clinical manifestations. Although invasive GAS (iGAS) infections are relatively uncommon, emm3/ST15 GAS is a highly virulent, invasive, and pathogenic strain. Global molecular epidemiology analysis has suggested that the frequency of emm3 GAS has been recently increasing.

Case presentation

A 14-year-old patient was diagnosed with streptococcal toxic shock syndrome and severe pneumonia, impaired renal function, and rhabdomyolysis. GAS was isolated from a culture of endotracheal aspirates and designated as KS030. Comparative genome analysis suggested that KS030 is classified as emm3 (emm-type) and ST15 (multilocus sequencing typing [MLST]), which is similar to iGAS isolates identified in the UK (2013) and Switzerland (2015).

Conclusions

We conclude that the global dissemination of emm3/ST15 GAS strain has the potential to cause invasive disease.
Hinweise

Electronic supplementary material

The online version of this article (10.​1186/​s12879-017-2870-2) contains supplementary material, which is available to authorized users.
Abkürzungen
GAS
Group A hemolytic Streptococcus
iGAS
Invasive GAS
MLST
Multilocus sequencing typing
SNVs
Single-nucleotide variations
STSS
Streptococcal toxic shock syndrome

Background

Streptococcus pyogenes (group A Streptococcus; GAS) is a major human pathogen that causes a wide spectrum of clinical manifestations, from common superficial skin infections and pharyngitis to invasive infections, such as bacteremia, meningitis, cellulitis, and pneumonia, and the more severe necrotizing fasciitis and streptococcal toxic shock syndrome (STSS). Invasive GAS (iGAS) infections, although relatively less common than non-iGAS infections, remain a significant global cause of morbidity and mortality. GAS strains differ widely in the degree of encapsulation, showing a mucoid morphology when cultured on blood agar plates [1]. Limited emm types, such as emm1, 3, 5, 6, and 18, which are often mucoid, have been associated with rheumatological effects [2] and are the most prevalent emm types found to cause iGAS infections worldwide, particularly emm1 and emm3 [3, 4].

Case presentation

A 14-year-old boy with complaints of fever above 39 °C and sore throat had received an intravenous infusion of fluid and antimicrobial agents for dehydration and bacterial infection at another clinic. Although he had been diagnosed with an immunoglobulin (Ig)G subclass deficiency (IgG4 single deficiency) in the past, he was not considered to be more susceptible to infection. Also, due to mental development delays, he had received special support education. Three days later, he was transported by ambulance to our hospital because of a loss of consciousness. On admission, the Glasgow Coma Scale was E1V1M3, body temperature was 41.7 °C, systolic blood pressure was 74 mmHg, hypotension was observed, SpO2 was 80%, and oxygen saturation was markedly reduced. Convulsions began during his treatment in the Emergency Department, so intravenous anticonvulsive drugs were administered. Endotracheal intubation was also performed for the management of ventilation. During the physical examination in the Emergency Department, both ocular conjunctiva were congested and erythema was present across his anterior chest. During chest auscultation, rhonchi were apparent. Chest computed tomography (CT) showed frosted glass shadows on both sides of his back (Fig. 1). There were no abnormal findings on a head CT scan.
Blood test results revealed a white blood cell count of 21,300/μl (neutrophils 83%), platelet count of 20.7 × 104/μl, C-reactive protein level of 33.84 mg/dl, blood urea nitrogen level of 50.9 mg/dl, creatinine level of 1.87 mg/dl, aspartate aminotransferase level of 72 U/L, alanine aminotransferase level of 20 U/L, lactic acid dehydrogenase level of 501 U/L, total bilirubin level of 0.5 mg/dl, gamma-glutamyltransferase level of 14 U/L, creatine kinase level of 2062 U/L, IgG level of 2507 mg/dl, IgM level of 88 mg/dl, and IgA level of 284 mg/dl. Rapid immunochromatographic testing of pharyngeal swabs was positive for GAS antigen. One week before the patient developed a fever, his brother developed a fever with pharyngitis, which was diagnosed as a GAS infection and treated with antimicrobials. Rapid testing results for influenza virus and adenovirus were negative.
Based on the above clinical findings, the patient was diagnosed with STSS and severe pneumonia, impaired renal function, and rhabdomyolysis. Antibiotics (vancomycin, clindamycin, and meropenem) and intravenous immunoglobulin therapy were administered to treat the severe infection. Also, continuous infusion of a vasopressor for hypotension and steroid pulse therapy for the severe pneumonia were administered. Transfusion, anticoagulation therapy, and antithrombin III supplementation therapy were performed because of complications from disseminated intravascular coagulation syndrome during the course of treatment. Due to the prior administration of intravenous antibiotics at the other clinic, his blood culture results were negative, but GAS was isolated from a culture of endotracheal aspirate (the strain was designated KS030). Therefore, the antimicrobial treatment was changed to cefotaxime administration for 14 days. On hospitalization day 3, the patient recovered from STSS, and the pneumonia improved on hospitalization day 9, thus the ventilator was subsequently removed. Rehabilitation was successful, and the patient was discharged on hospitalization day 19 with no sequelae.
Whole-genome sequencing of S. pyogenes KS030 was performed by the hybrid assembly of reads obtained by an Illumina NextSeq 500 sequencer (2 × 150-mer; median coverage: ×218) and a PacBio RSII single-molecule real-time sequencer (N50 read length: 14,559; median coverage: ×279.68). The complete genomic sequence of S. pyogenes KS030 was annotated using the gene prediction program Prodigal and deposited in a public database (1,900,008 bp; accession number: AP018337). KS030 is classified as an emm3 (emm-type) and ST15 (multilocus sequencing typing [MLST]) strain that has a similar genomic organization as the S. pyogenes SSI-1 strain isolated from an STSS patient in Japan [5]. To characterize the molecular epidemiology of KS030, all publicly available genome sequences of GAS strains, including ST15, ST315, and ST406, were retrieved (see Additional file 1) and compared using bwaMEM read mapping against the KS030 complete genome sequence as a reference. After excluding repeated regions and six prophage sequences throughout the whole genome sequence, 80.3% of the region was assigned as the core genome sequence among 484 GAS strains, which resulted in the identification of a total of 2752 single-nucleotide variations (SNVs). The core genome of MLST (cgMLST) was determined using the above SNVs, and the phylogeny was generated using the maximum likelihood phylogenetic method with RAxML [6]. The results indicated that KS030 is very similar to the iGAS isolate SAMEA2144795 identified in the United Kingdom in 2013 and the SAMEA4520962 isolate identified in Switzerland in 2015 (Fig. 2). The KS030 genome sequence also suggested that the unique 1-bp deletion (7 × to 6 × adenine nucleotides) in the rocA gene led to C-terminal truncation, as well as common genetic features among emm3 GAS isolates (see Additional file 1).

Discussion and conclusions

The emm3/ST15 GAS strain has the potential to be highly virulent, demonstrating invasive pathogenicity [4, 7] and high capsule production, leading to a mucoid morphology [3] and early macrophage cell death [8]. Intriguingly, the molecular epidemiology of GAS in Japan suggests that the frequency of emm3 GAS has been recently increasing (2%–6.9% in 2010–2012) but is not as dominant as emm1 (>60%) [9]. Moreover, the natural rocA mutation within M3 isolates generates an absence of RocA activity on the CovR/S two-component system resulting in the de-repression of more than a dozen immunomodulatory virulence factors, leading to the severity of invasive infections [10]. We conclude that the global dissemination of emm3/ST15 has the potential to cause invasive disease.

Acknowledgements

Not Applicable.

Funding

This work was supported by the Research Program on Emerging and Re-emerging Infectious Diseases from the Japan Agency for Medical Research and Development, AMED (grant number: 17fk0108219j0002). This work was partially supported by a grant-in-aid for Scientific Research (grant number: 26,460,542). The funding agencies had no role in the study design, data collection and analysis, decision to publish, or manuscript preparation.

Availability of data and materials

The complete genomic sequence of S. pyogenes KS030 was annotated using Prodigal and deposited in a public database (accession number: AP018337). The dataset supporting the conclusions of this article is included within the article and its additional file.
The study protocol was approved by the National Institute of Infectious Diseases in Japan (Approval No. 677) and was conducted in accordance with the tenets of the Declaration of Helsinki. Written informed consent was obtained from the parents of the patient for the use of their child's sample for further genomic analysis
Written informed consent was obtained from the parents of the patient for the use of their child’s sample for further genomic analysis and the publication of this manuscript. The consent form is held by the authors’ institution and is available for review.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Literatur
1.
Zurück zum Zitat Stollerman GH, Dale JB. The importance of the group a Streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clin Infect Dis. 2008;46(7):1038–45.CrossRefPubMed Stollerman GH, Dale JB. The importance of the group a Streptococcus capsule in the pathogenesis of human infections: a historical perspective. Clin Infect Dis. 2008;46(7):1038–45.CrossRefPubMed
2.
Zurück zum Zitat Veasy LG, Tani LY, Daly JA, Korgenski K, Miner L, Bale J, Kaplan EL, Musser JM, Hill HR. Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics. 2004;113(3 Pt 1):e168–72.CrossRefPubMed Veasy LG, Tani LY, Daly JA, Korgenski K, Miner L, Bale J, Kaplan EL, Musser JM, Hill HR. Temporal association of the appearance of mucoid strains of Streptococcus pyogenes with a continuing high incidence of rheumatic fever in Utah. Pediatrics. 2004;113(3 Pt 1):e168–72.CrossRefPubMed
3.
Zurück zum Zitat Tamayo E, Montes M, Garcia-Medina G, Garcia-Arenzana JM, Perez-Trallero E. Spread of a highly mucoid Streptococcus pyogenes emm3/ST15 clone. BMC Infect Dis. 2010;10:233.CrossRefPubMedPubMedCentral Tamayo E, Montes M, Garcia-Medina G, Garcia-Arenzana JM, Perez-Trallero E. Spread of a highly mucoid Streptococcus pyogenes emm3/ST15 clone. BMC Infect Dis. 2010;10:233.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Chalker V, Jironkin A, Coelho J, Al-Shahib A, Platt S, Kapatai G, Daniel R, Dhami C, Laranjeira M, Chambers T, et al. Genome analysis following a national increase in scarlet fever in England 2014. BMC Genomics. 2017;18(1):224.CrossRefPubMedPubMedCentral Chalker V, Jironkin A, Coelho J, Al-Shahib A, Platt S, Kapatai G, Daniel R, Dhami C, Laranjeira M, Chambers T, et al. Genome analysis following a national increase in scarlet fever in England 2014. BMC Genomics. 2017;18(1):224.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Nakagawa I, Kurokawa K, Yamashita A, Nakata M, Tomiyasu Y, Okahashi N, Kawabata S, Yamazaki K, Shiba T, Yasunaga T, et al. Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution. Genome Res. 2003;13(6A):1042–55.CrossRefPubMedPubMedCentral Nakagawa I, Kurokawa K, Yamashita A, Nakata M, Tomiyasu Y, Okahashi N, Kawabata S, Yamazaki K, Shiba T, Yasunaga T, et al. Genome sequence of an M3 strain of Streptococcus pyogenes reveals a large-scale genomic rearrangement in invasive strains and new insights into phage evolution. Genome Res. 2003;13(6A):1042–55.CrossRefPubMedPubMedCentral
6.
7.
Zurück zum Zitat Meehan M, Murchan S, Bergin S, O'Flanagan D, Cunney R. Increased incidence of invasive group a streptococcal disease in Ireland, 2012 to 2013. Euro Surveill. 2013;18(33):20556.CrossRefPubMed Meehan M, Murchan S, Bergin S, O'Flanagan D, Cunney R. Increased incidence of invasive group a streptococcal disease in Ireland, 2012 to 2013. Euro Surveill. 2013;18(33):20556.CrossRefPubMed
8.
Zurück zum Zitat Dinis M, Plainvert C, Longo M, Guignot J, Gabriel C, Poyart C, Fouet A: Group A Streptococcus emm3 strains induce early macrophage cell death. Pathog Dis. 2016;74(2). doi:10.1093/femspd/ftv124. Epub 2015 Dec 23. PMID: 26702632. Dinis M, Plainvert C, Longo M, Guignot J, Gabriel C, Poyart C, Fouet A: Group A Streptococcus emm3 strains induce early macrophage cell death. Pathog Dis. 2016;74(2). doi:10.​1093/​femspd/​ftv124. Epub 2015 Dec 23. PMID: 26702632.
9.
Zurück zum Zitat Ikebe T, Tominaga K, Shima T, Okuno R, Kubota H, Ogata K, Chiba K, Katsukawa C, Ohya H, Tada Y, et al. Increased prevalence of group a Streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2010 to 2012. Epidemiol Infect. 2015;143(4):864–72.CrossRefPubMed Ikebe T, Tominaga K, Shima T, Okuno R, Kubota H, Ogata K, Chiba K, Katsukawa C, Ohya H, Tada Y, et al. Increased prevalence of group a Streptococcus isolates in streptococcal toxic shock syndrome cases in Japan from 2010 to 2012. Epidemiol Infect. 2015;143(4):864–72.CrossRefPubMed
10.
Zurück zum Zitat Miller EW, Danger JL, Ramalinga AB, Horstmann N, Shelburne SA, Sumby P. Regulatory rewiring confers serotype-specific hyper-virulence in the human pathogen group a Streptococcus. Mol Microbiol. 2015;98(3):473–89.CrossRefPubMedPubMedCentral Miller EW, Danger JL, Ramalinga AB, Horstmann N, Shelburne SA, Sumby P. Regulatory rewiring confers serotype-specific hyper-virulence in the human pathogen group a Streptococcus. Mol Microbiol. 2015;98(3):473–89.CrossRefPubMedPubMedCentral
Metadaten
Titel
Streptococcal toxic shock syndrome caused by the dissemination of an invasive emm3/ST15 strain of Streptococcus pyogenes
verfasst von
Tsuyoshi Sekizuka
Emina Nai
Tomohiro Yoshida
Shota Endo
Emi Hamajima
Satoka Akiyama
Yoji Ikuta
Natsuko Obana
Takahiro Kawaguchi
Kenta Hayashi
Masahiro Noda
Tomoko Sumita
Masayuki Kokaji
Tatsuo Katori
Masanori Hashino
Kunihiro Oba
Makoto Kuroda
Publikationsdatum
01.12.2017
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2017
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-017-2870-2

Weitere Artikel der Ausgabe 1/2017

BMC Infectious Diseases 1/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.